Skip to content

Tenecteplase Thrombolysis in Acute Ischemic Stroke: A Prospective Registry Study

Tenecteplase Thrombolysis in Acute Ischemic Stroke: A Prospective Registry Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111627
Enrollment
Unknown
Registered
2025-11-03
Start date
2025-11-04
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

Tenecplase/alteplase group:None

Sponsors

Fudan University, Huashan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients over 18 years old who received intravenous thrombolysis with TNK or rt-PA within 24 hours of the onset of acute ischemic stroke 2. To avoid interfering with medication, you should obtain your consent during the 3-7 days of hospitalization after taking the medicine. If necessary (such as in cases of consciousness disorder, aphasia, etc.), obtain the informed consent of your guardian

Exclusion criteria

Exclusion criteria: Cases where the time from onset to treatment is unknown, cases lacking 24-72 hours of follow-up images, or cases with missing data exceeding 40% of the total data, and cases diagnosed with non-ischemic stroke upon discharge.

Design outcomes

Secondary

MeasureTime frame
Symptomatic intracranial hemorrhage occurred within 3 days of onset;

Primary

MeasureTime frame
90-day mRS Score;

Countries

China

Contacts

Public ContactXin Cheng

Fudan University, Huashan Hospital

ymifi@hotmail.com+86 138 1837 7071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026